www.fdanews.com/articles/196477-oncosils-pancreatic-cancer-treatment-gets-ce-mark
OncoSil’s Pancreatic Cancer Treatment Gets CE Mark
April 1, 2020
OncoSil Medical has earned a CE Mark for its OncoSil implant used to treat pancreatic cancer alongside chemotherapy.
The radioactive implant is placed directly in a patient’s pancreatic tumor using endoscopic ultrasound. It can also be used to treat other solid tumor types such as liver and biliary duct cancer.
OncoSil previously received a breakthrough device designation from the FDA.